(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer.

The need for flexible logistics solutions is at an all-time high. In this week's episode of Disruption Interruption, Shaun Savage, CEO of GoShare, explores how his innovative platform is ...

We recently compiled a list of the 10 AI News That You Should Not Miss. In this article, we are going to take a look at where ...

Soticlestat is under clinical development by Takeda Pharmaceutical and currently in Phase II for Epileptic Encephalopathy.

When Chris Leonard moved to the Los Angeles area roughly a decade ago, he knew exactly where he wanted to call home: the ...